Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysemaAdditional orphan designation ...
Sanofi (EURONEXT: SAN) announced Wednesday that its investigational therapy, efdoralprin alfa, has received orphan drug ...
Investing.com -- Sanofi (EURONEXT:SAN) said Wednesday that its investigational therapy efdoralprin alfa has received orphan ...
December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: Fourth quarter & full year 2025 results (sanofi.com) As for each ...
Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...
The PERSEUS trial was a global, double-blind, randomized Phase 3 study comparing tolebrutinib to placebo in PPMS patients.
Fintel reports that on December 15, 2025, JEFFERIES maintained coverage of Sanofi (OTCPK:SNYNF) with a Buy recommendation. Analyst Price Forecast Suggests 29.28% Upside As of November 17, 2025, the ...
Two large deals and an acquisition, all totaling about $4.64 billion, are helping close out a strong year. Yarrow Bioscience Inc. cut a potentially $1.36 billion deal with Shanghai Scizeng Medical ...
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting ...
Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...
ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results